A New Treatment Opportunity After Relapsed T-Cell Lymphoma

When 59-year-old Sergei from Russia experienced a relapse of angioimmunoblastic T-cell lymphoma (AITL) following autologous hematopoietic stem cell transplantation, the disease progressed quickly. For Sergei and his family, the biggest question was whether there were still treatment options left to explore.

They came to GoBroad Healthcare Group seeking another opinion and the possibility of further treatment.

After reviewing Sergei’s previous treatment and reassessing his condition, Dr. Jing Pan’s team found that the situation offered more options than the family had initially expected. Sergei had not yet received standard second-line treatment, which meant there was still room to explore established treatment approaches before moving on to other options.

Based on his condition, the team started targeted therapy. At the same time, cells collected from Sergei were cryopreserved, keeping CAR-T cell therapy available as a possible future option should it become necessary.

So far, there have been some encouraging changes. The enlarged lymph nodes in Sergei’s neck have become smaller, and the feeling of swelling that had previously troubled him has subsided.

It is still early in the course of treatment, and further follow-up will be needed to understand how well and how long Sergei responds. But for Sergei and his family, the reassessment brought something important: a clearer treatment path and more options for what may come next.

Sergei’s experience also shows why a thorough reassessment can matter after lymphoma relapses. Disease progression after previous treatment does not necessarily mean that every treatment option has been exhausted. Understanding what has—and has not—already been tried can help the medical team plan the next step while keeping future possibilities open.

Individual treatment plans and outcomes vary. This patient story is for informational purposes only and does not constitute medical advice.